Ivercare
Executive summary
IverCare is Farnam’s branded ivermectin paste formulated and FDA‑approved for equine deworming and bot control, sold as a single‑dose oral syringe that treats horses by weight and is explicitly labeled “for horses only” and “not for use in humans” [1] [2]. The product is widely distributed through farm retailers and veterinary supply channels and carries standard veterinary warnings about species‑specific use, environmental impacts, and potential adverse reactions in heavily infected animals [3] [2].
1. What IverCare is and what it treats
IverCare (ivermectin paste) 1.87% is an anthelmintic/boticide intended to control a broad range of equine parasites—large and small strongyles, ascarids, pinworms, bots, lungworms and other nematodes—with a single labeled dose when administered per weight‑based calibrations on the syringe [1] [4].
2. Regulatory status and labeling: equine only
The manufacturer and FDA records make the product’s approved scope clear: IverCare is FDA‑approved for use in horses only and “has not been tested in humans and is not approved for use with humans,” language carried across the product label, DailyMed and retailer listings [1] [2] [5].
3. How it’s supplied and dosed in practice
IverCare is supplied as apple‑flavored paste in calibrated syringes intended to be administered orally, with each syringe sized to treat horses up to specified weight limits—commonly 1,250–1,500 lb depending on the listing—and instructions to follow the label for dosing and handling [4] [3] [6].
4. Safety warnings, adverse reactions, and environmental notes
The label and DailyMed safety information warn that IverCare should not be used in horses intended for human consumption and emphasize handwashing and avoiding ingestion during handling; adverse reactions such as swelling and itching have been reported in horses heavily infected with neck threadworm microfilariae, and the label cautions that parasite resistance can develop and that ivermectin residues may harm aquatic organisms [2] [7].
5. Veterinary guidance and limitations of the record
Manufacturers and retailer blurbs consistently advise consulting a veterinarian for diagnosis and parasite control programs and note foals should begin treatment at 6–8 weeks with follow‑up schedules customized to the herd—recommendations grounded in product labeling rather than independent clinical studies in the provided reporting [7] [8]. The sources do not provide head‑to‑head efficacy trials, long‑term resistance surveillance data, or human clinical data, so those areas cannot be evaluated from the supplied material [4] [9].
6. Marketplace presence and variants with similar names
IverCare is sold through mainstream farm and tack retailers and online vendors, and multiple product pages repeat the same label claims and dosing guidance, which indicates wide market availability for equine owners [3] [6]. Separately, other products and web pages use similar names (e.g., “Ivercare” tablet listings and third‑party pharmacy sites) that may refer to different formulations or human antiparasitic tablets; the provided record includes an unrelated online pharmacy site and tablet entries that are not the Farnam equine paste, so care is required when interpreting product names across contexts [10] [11].
7. Bottom line: appropriate use and common misconceptions
From the manufacturer and regulatory summaries, IverCare is a labeled, FDA‑approved equine ivermectin paste effective for many horse parasites when used per label and under veterinary guidance, and it is explicitly not approved or tested for human use—claims that are consistently repeated across product and safety documents [1] [2]. The supplied reporting does not address off‑label human use, misuse trends, overdose case series, nor comparative effectiveness versus other equine anthelmintics; therefore conclusions on those topics cannot be drawn from these sources [9].